Trials / Enrolling By Invitation
Enrolling By InvitationNCT05654883
New York City Observational Study of Mpox Immunity
New York City Observational Study of Mpox Immunity: NYC OSMI
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 174 (estimated)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose subcutaneous (upper arm) vaccine. The resulting data will fill knowledge gaps, inform public health practices, and address community concerns about the absence of data for low-dose intradermal mpox vaccinations in people living with HIV.
Conditions
Timeline
- Start date
- 2022-11-11
- Primary completion
- 2023-09-11
- Completion
- 2026-06-01
- First posted
- 2022-12-16
- Last updated
- 2025-10-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05654883. Inclusion in this directory is not an endorsement.